However, CRAF deficiency does not affect tumor development of pancreatic ductal carcinoma (PDAC) with KRASG12D or KRASG12V, while concomitant ablation of EGFR and CRAF completely prevent PDAC development driven by KRASG12V/Trp53 mutation.168, 169. This evidence concerns the gene RAF1 and pancreatic ductal adenocarcinoma.